DAIC Articles

Texas Heart Institute (THI) was awarded a prestigious four-year, $2.39 million grant from the National Institutes of Health (NIH) to explore further the development of a novel pacemaker system that is both leadless and wirelessly powered.

Although common femoral artery (CFA) endarterectomy is still considered the gold standard treatment for patients with CFA stenosis, 12-month follow-up results of the VMI-CFA study showed that endovascular stent repair is a safe and effective alternative.

The Absorb bioresorbable stent (BVS) demonstrated good patency and clinical outcomes in patients with chronic limb-threatening ischemia (CLTI) in the DISAPEAR Registry.

Real-world, four-year study results of the In.Pact Admiral drug-coated balloon (DCB) demonstrate long-term, sustained clinical benefit and safety with low amputation and mortality rates in peripheral artery disease (PAD) patients treated with the device.

Edwards Lifesciences announced it received European CE mark to expand use of the Edwards Sapien 3 transcatheter aortic valve replacement (TAVR) device for the treatment of patients diagnosed with aortic stenosis who are at low risk for open-heart surgery.

The latest in interventional cardiology clinical data and new device technologies were highlighted at the annual Transcatheter Cardiovascular Therapeutics (TCT) conference.

Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (DAIC) magazine website from the month of October 2019. This is based on the website’s 231,423 pageviews for the month:

This is a photo essay of the interventional cardiology and structural heart technologies on the expo floor and discussed in sessions during the Trancatheter Cardiovascular Therapeutics (TCT)  2019 annual meeting. Each photo has its own caption explaining the image in detail.

In a large series of iliac vein stent cases, a blinded comparison found intravascular ultrasound (IVUS) superior to venography in determining the proper location of treatment zones. This is reported in the November 2019 edition of the Journal of Vascular Surgery: Venous and Lymphatic Disorders.[1]

Baylis Medical announced the first North American use of its EPstar Fixed Electrophysiology Catheters. The EPstar catheters make available the smallest diagnostic catheter in the North American electrophysiology market, allowing physicians to reach previously inaccessible areas of the heart for procedure mapping.